NCT06823284View on ClinicalTrials.gov

To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

February 12, 2025

Study Completion Date

February 24, 2025

Conditions
Healthy
Interventions
DRUG

Esflurbiprofen Topical System

The total of two TK-254RX per day for 5 days (one patch applied to left and right lower leg above ankle)

DRUG

Flurbiprofen tablet

3 tablets per day for 4 days

Trial Locations (1)

99084

SocraTec R&D GmbH Clinical Pharmacology Unit, Mainzerhofplatz 14

All Listed Sponsors
collaborator

SocraTec R&D GmbH

OTHER

collaborator

SocraMetrics GmbH

INDUSTRY

collaborator

HWI pharma services GmbH

INDUSTRY

lead

Teikoku Seiyaku Co., Ltd.

INDUSTRY

NCT06823284 - To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects | Biotech Hunter | Biotech Hunter